Price (delayed)
$1.18
Market cap
$10.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.77
Enterprise value
$9.21M
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
There are no recent dividends present for CTXR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.